Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding

Nucleic Acids Research

Volumn 40, Issue 13, 2012, Pages 6353-6366

  Andresen, Cecilia ^a   Helander, Sara ^a   Lemak, Alexander ^b,c,d   Farès, Christophe ^b,c,d,f   Csizmok, Veronika ^e   Carlsson, Jonas ^a   Penn, Linda Z ^b,d   Forman Kay, Julie D ^b,e   Arrowsmith, Cheryl H ^b,c,d   Lundström, Patrik ^a   Sunnerhagen, Maria ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f MAX PLANCK INSTITUT FÜR KOHLENFORSCHUNG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; MYC PROTEIN; PROTEIN BIN1; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; COMPLEX FORMATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; TRANSACTIVATION;

BINDING SITES; HUMANS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MYC; SRC HOMOLOGY DOMAINS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84864424878     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gks263     Document Type: Article

References (81)

1. Meyer, N. and Penn, L.Z. (2008) Reflecting on 25 years with MYC. Nat. Rev. Cancer, 8, 976-990.
2. Eilers, M. and Eisenman, R.N. (2008) Myc's broad reach. Genes Dev., 22, 2755-2766.
3. Agrawal, P., Yu, K., Salomon, A.R. and Sedivy, J.M. (2010) Proteomic profiling of Myc-associated proteins. Cell Cycle, 9, 4908-4921.
4. Kim, J., Woo, A.J., Chu, J., Snow, J.W., Fujiwara, Y., Kim, C.G., Cantor, A.B. and Orkin, S.H. (2010) A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell, 143, 313-324.
5. Kalkat, M., Wasylishen, A.R., Kim, S.S. and Penn, L. (2011) More than MAX: discovering the Myc interactome. Cell Cycle, 10, 374-379.
6. Nair, S.K. and Burley, S.K. (2003) X-ray structures of Myc-Max and Mad-Max recognizing DNA: molecular bases of regulation by proto-oncogenic transcription factors. Cell, 112, 193-205.
7. Dang, C.V., O'Donnell, K.A., Zeller, K.I., Nguyen, T., Osthus, R.C. and Li, F. (2006) The C-Myc target gene network. Semin. Cancer Biol., 16, 253-264.
8. Dang, C.V. (2010) Enigmatic MYC conducts an unfolding systems biology symphony. Genes Cancer, 1, 526-531.
9. Cole, M.D. and Cowling, V.H. (2008) Transcription-independent functions of MYC: regulation of translation and DNA replication. Nat. Rev. Mol. Cell Biol., 9, 810-815.
10. Kato, G.J., Barrett, J., Villa-Garcia, M. and Dang, C.V. (1990) An amino-terminal C-MYC domain required for neoplastic transformation activates transcription. Mol. Cell. Biol., 10, 5914-5920.
11. Stone, J., de Lange, T., Ramsay, G., Jakobovits, E., Bishop, J.M., Varmus, H. and Lee, W. (1987) Definition of regions in human C-MYC that are involved in transformation and nuclear localization. Mol. Cell. Biol., 7, 1697-1709.
12. Freytag, S., Dang, C. and Lee, W. (1990) Definition of the activities and properties of C-MYC required to inhibit cell differentiation. Cell Growth Differ., 1, 339-343.
13. Evan, G.I., Wyllie, A.H., Gilbert, C.S., Littlewood, T.D., Land, H., Brooks, M., Waters, C.M., Penn, L.Z. and Hancock, D.C. (1992) Induction of apoptosis in fibroblasts by C-MYC protein. Cell, 69, 119-128.
14. Varlakhanova, N.V. and Knoepfler, P.S. (2009) Acting locally and globally: Myc's ever-expanding roles on chromatin. Cancer Res., 69, 7487-7490.
15. van Riggelen, J., Yetil, A. and Felsher, D.W. (2010) MYC as a regulator of ribosome biogenesis and protein synthesis. Nat. Rev. Cancer, 10, 301-309.
16. Cowling, V.H. and Cole, M.D. (2006) Mechanism of transcriptional activation by the Myc oncoproteins. Semin. Cancer Biol., 16, 242-252.
17. Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W.C., Stukenberg, P.T., Shenolikar, S., Uchida, T. et al. (2004) A signalling pathway controlling C-MYC degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol., 6, 308-318.
18. Hann, S.R. (2006) Role of post-translational modifications in regulating C-MYC proteolysis, transcriptional activity and biological function. Semin. Cancer Biol., 16, 288-302.
19. Hydbring, P., Bahram, F., Su, Y., Tronnersjö, S., Högstrand, K., von der Lehr, N., Sharifi, H.R., Lilischkis, R., Hein, N., Wu, S. et al. (2010) Phosphorylation by CDK2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc. Natl Acad. Sci. USA, 107, 58-63.
20. Vervoorts, J., Lüscher-Firzlaff, J. and Lüscher, B. (2006) The ins and outs of Myc regulation by posttranslational mechanisms. J. Biol. Chem., 281, 34725-34729.
21. Bahram, F., von der Lehr, N., Cetinkaya, C. and Larsson, L.-G. (2000) C-MYC hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood, 95, 2104-2110.
22. Wang, X., Cunningham, M., Zhang, X., Tokarz, S., Laraway, B., Troxell, M. and Sears, R.C. (2011) Phosphorylation regulates C-Myc's oncogenic activity in the mammary gland. Cancer Res., 71, 925-936.
23. Welcker, M. and Clurman, B.E. (2008) FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer, 8, 83-93.
24. Pineda-Lucena, A., Ho, C.S.W., Mao, D.Y.L., Sheng, Y., Laister, R.C., Muhandiram, R., Lu, Y., Seet, B.T., Katz, S., Szyperski, T. et al. (2005) A structure-based model of the C-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and C-Myc phosphorylation are key binding determinants. J. Mol. Biol., 351, 182-194.
25. Sakamuro, D., Elliott, K.J., Wechsler-Reya, R. and Prendergast, G.C. (1996) BIN1 is a novel Myc-interacting protein with features of a tumour suppressor. Nat. Genet., 14, 69-77.
26. Ge, K., Minhas, F., Duhadaway, J., Mao, N.-C., Wilson, D., Buccafusca, R., Sakamuro, D., Nelson, P., Malkowicz, S.B., Tomaszewski, J. et al. (2000) Loss of heterozygosity and tumor suppressor activity of BIN1 in prostate carcinoma. Int. J. Cancer, 86, 155-161.
27. Elliott, K., Sakamuro, D., Basu, A., Du, W., Wunner, W., Staller, P., Gaubatz, S., Zhang, H., Prochownik, E., Eilers, M. et al. (1999) BIN1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene, 18, 3564-3573.
28. DuHadaway, J.B., Sakamuro, D., Ewert, D.L. and Prendergast, G.C. (2001) BIN1 mediates apoptosis by C-Myc in transformed primary cells. Cancer Res., 61, 3151-3156.
29. Telfer, J.F., Urquhart, J. and Crouch, D.H. (2005) Suppression of MEK/ERK signalling by Mcy: role of Bin-1. Cell. Signalling, 17, 701-708.
30. Kinney, E.L., Tanida, S., Rodrigue, A.A., Johnson, J.K., Tompkins, V.S. and Sakamuro, D. (2008) Adenovirus E1A oncoprotein liberates C-Mcy activity to promote cell proliferation through abating BIN1 expression via an RB/E2F1-dependent mechanism. J. Cell. Physiol., 216, 621-631.
31. Fladvad, M., Zhou, K.S., Moshref, A., Pursglove, S., Safsten, P. and Sunnerhagen, M. (2005) N and C-terminal sub-regions in the C-Mcy transactivation region and their joint role in creating versatility in folding and binding. J. Mol. Biol., 346, 175-189.
32. Dyson, H.J. and Wright, P.E. (2005) Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol., 6, 197-208.
33. Mittag, T., Kay, L.E. and Forman-Kay, J.D. (2010) Protein dynamics and conformational disorder in molecular recognition. J. Mol. Recognit., 23, 105-116.
34. McEwan, I.J., Dahlman-Wright, K., Ford, J. and Wright, A.P.H. (1996) Functional interaction of the C-Mcy transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding. Biochemistry, 35, 9584-9593.
35. Burton, R.A., Mattila, S., Taparowsky, E.J. and Post, C.B. (2006) B-Mcy: N-terminal recognition of Mcy binding proteins. Biochemistry, 45, 9857-9865.
36. Ponzielli, R., Katz, S., Barsyte-Lovejoy, D. and Penn, L.Z. (2005) Cancer therapeutics: targeting the dark side of Mcy. Eur. J. Cancer, 41, 2485-2501.
37. Yada, M., Hatakeyama, S., Kamura, T., Nishiyama, M., Tsunematsu, R., Imaki, H., Ishida, N., Okumura, F., Nakayama, K. and Nakayama, K.I. (2004) Phosphorylation-dependent degradation of C-Mcy is mediated by the F-box protein Fbw7. EMBO J., 23, 2116-2125.
38. Arnold, H.K., Zhang, X., Daniel, C.J., Tibbitts, D., Escamilla-Powers, J., Farrell, A., Tokarz, S., Morgan, C. and Sears, R.C. (2009) The Axin1 scaffold protein promotes formation of a degradation complex for C-Mcy. EMBO J., 28, 500-512.
39. Kanelis, V., Chong, P.A. and Forman-Kay, J.D. (2011) NMR spectroscopy to study the dynamics and interactions of CFTR. Methods Mol Biol, 741, 377-403.
40. Lemak, A., Gutmanas, A., Chitayat, S., Karra, M., Farè s, C., Sunnerhagen, M. and Arrowsmith, C. (2011) A novel strategy for NMR resonance assignment and protein structure determination. J. Biomol. NMR, 49, 27-38.
41. Farrow, N.A., Muhandiram, R., Singer, A.U., Pascal, S.M., Kay, C.M., Gish, G., Shoelson, S.E., Pawson, T., Forman-Kay, J.D. and Kay, L.E. (1994) Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation. Biochemistry, 33, 5984-6003.
42. Korzhnev, D.M., Skrynnikov, N.R., Millet, O., Torchia, D.A. and Kay, L.E. (2002) An NMR experiment for the accurate measurement of heteronuclear spin-lock relaxation rates. J. Am. Chem. Soc., 124, 10743-10753.
43. Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J. and Bax, A. (1995) NMRPipe: A multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR, 6, 277-293.
44. Goddard, T.G. and Kneller, D.G. SPARKY 3, University of California, San Francisco.
45. Mulder, F.A.A., Schipper, D., Bott, R. and Boelens, R. (1999) Altered flexibility in the substrate-binding site of related native and engineered high-alkaline Bacillus subtilisins. J. Mol. Biol., 292, 111-123.
46. Schumann, F., Riepl, H., Maurer, T., Gronwald, W., Neidig, K.-P. and Kalbitzer, H. (2007) Combined chemical shift changes and amino acid specific chemical shift mapping of protein-protein interactions. J. Biomol. NMR, 39, 275-289.
47. Marsh, J.A., Singh, V.K., Jia, Z. and Forman-Kay, J.D. (2006) Sensitivity of secondary structure propensities to sequence differences between A-and G-synuclein: Implications for fibrillation. Protein Sci., 15, 2795-2804.
48. Mosteller, F. and Tukey, J.W. (1977) Data Analysis and Regression-A Second Course in Statistics. Addison-Wesley Publishing Company Inc., Philippines.
49. Palmer, A.G. and Massi, F. (2006) Characterization of the dynamics of biomacromolecules using rotating-frame spin relaxation NMR spectroscopy. Chem. Rev., 106, 1700-1719.
50. Biacore. (2004) BIAevaluation 4.0 Software Handbook, Biacore AB: Uppsala, Sweden.
51. Hedlund, J., Johansson, J. and Persson, B. (2009) BRICHOS-a superfamily of multidomain proteins with diverse functions. BMC Res. Notes, 2, 180.
52. He, B., Wang, K., Liu, Y., Xue, B., Uversky, V.N. and Dunker, A.K. (2009) Predicting intrinsic disorder in proteins: an overview. Cell Res., 19, 929-949.
53. Linding, R., Jensen, L.J., Diella, F., Bork, P., Gibson, T.J. and Russell, R.B. (2003) Protein disorder prediction: implications for structural proteomics. Structure, 11, 1453-1459.
54. Xue, B., Dunbrack, R.L., Williams, R.W., Dunker, A.K. and Uversky, V.N. (2010) PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. BBA-Proteins Proteom., 1804, 996-1010.
55. Wang, L. and Sauer, U.H. (2008) OnD-CRF: predicting order and disorder in proteins conditional random fields. Bioinformatics, 24, 1401-1402.
56. Dosztá nyi, Z., Mészá ros, B. and Simon, I. (2009) ANCHOR: web server for predicting protein binding regions in disordered proteins. Bioinformatics, 25, 2745-2746.
57. McMahon, S.B., Van Buskirk, H.A., Dugan, K.A., Copeland, T.D. and Cole, M.D. (1998) The novel ATM-related protein TRRAP is an essential cofactor for the C-Mcy and E2F oncoproteins. Cell, 94, 363-374.
58. Faiola, F., Liu, X., Lo, S., Pan, S., Zhang, K., Lymar, E., Farina, A. and Martinez, E. (2005) Dual Regulation of C-Mcy by p300 via Acetylation-Dependent Control of Mcy Protein Turnover and Coactivation of Mcy-Induced Transcription. Mol. Cell. Biol., 25, 10220-10234.
59. Huang, A., Ho, C.S.W., Ponzielli, R., Barsyte-Lovejoy, D., Bouffet, E., Picard, D., Hawkins, C.E. and Penn, L.Z. (2005) Identification of a novel C-Mcy protein interactor, JPO(2), with transforming activity in medulloblastoma cells. Cancer Res., 65, 5607-5619.
60. Baker, J.M., Hudson, R.P., Kanelis, V., Choy, W.Y., Thibodeau, P.H., Thomas, P.J. and Forman-Kay, J.D. (2007) CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices. Nat. Struct. Mol. Biol., 14, 738-745.
61. Pinheiro, A.S., Marsh, J.A., Forman-Kay, J.D. and Peti, W. (2011) Structural signature of the MYPT1-1 interaction. J. Am. Chem. Soc., 133, 73-80.
62. Kelker, M.S., Page, R. and Peti, W. (2009) Crystal structures of protein phosphatase-1 bound to nodularin-R and tautoMcyin: a novel scaffold for structure-based drug design of serine/threonine phosphatase inhibitors. J. Mol. Biol., 385, 11-21.
63. Klein-Seetharaman, J., Oikawa, M., Grimshaw, S.B., Wirmer, J., Duchardt, E., Ueda, T., Imoto, T., Smith, L.J., Dobson, C.M. and Schwalbe, H. (2002) Long-range interactions within a nonnative protein. Science, 295, 1719-1722.
64. Wüthrich, K. (1986) NMR of Proteins and Nucleic Acids. Wiley, New York.
65. Oster, S.K., Ho, C.S.W., Soucie, E.L. and Penn, L.Z. (2002) Adv. Cancer Res., 84, 81-154.
66. Sakamuro, D. and Prendergast, G.C. (1999) New Mcy-interacting proteins: a second Mcy network emerges. Oncogene, 18, 2942-2954.
67. Kaustov, L., Yi, G.S., Ayed, A., Bochkareva, E., Bochkarev, A. and Arrowsmith, C.H. (2006) p53 transcriptional activation domain: a molecular chameleon? Cell Cycle, 5, 489-494.
68. Botuyan, M.V., Momand, J. and Chen, Y. (1997) Solution conformation of an essential region of the p53 transactivation domain. Fold. Des., 2, 331-342.
69. Lee, H., Mok, K.H., Muhandiram, R., Park, K.-H., Suk, J.-E., Kim, D.-H., Chang, J., Sung, Y.C., Choi, K.Y. and Han, K.-H. (2000) Local structural elements in the mostly unstructured transcriptional activation domain of human p53. J. Biol. Chem., 275, 29426-29432.
70. Kussie, P.H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A.J. and Pavletich, N.P. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274, 948-953.
71. Di Lello, P., Jenkins, L.M.M., Jones, T.N., Nguyen, B.D., Hara, T., Yamaguchi, H., Dikeakos, J.D., Appella, E., Legault, P. and Omichinski, J.G. (2006) Structure of the Tfb1/p53 complex: insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Molecular Cell, 22, 731-740.
72. Feng, H., Jenkins, L.M.M., Durell, S.R., Hayashi, R., Mazur, S.J., Cherry, S., Tropea, J.E., Miller, M., Wlodawer, A., Appella, E. et al. (2009) Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. Structure, 17, 202-210.
73. Bochkareva, E., Kaustov, L., Ayed, A., Yi, G.-S., Lu, Y., Pineda-Lucena, A., Liao, J.C.C., Okorokov, A.L., Milner, J., Arrowsmith, C.H. et al. (2005) Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc. Natl Acad. Sci. USA, 102, 15412-15417.
74. Lee, C.W., Martinez-Yamout, M.A., Dyson, H.J. and Wright, P.E. (2010) Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein. Biochemistry, 49, 9964-9971.
75. Hu, B., Gilkes, D.M. and Chen, J. (2007) Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res., 67, 8810-8817.
76. Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S.G. et al. (2009) Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc. Natl Acad. Sci. USA, 106, 4665-4670.
77. Liu, M., Li, C., Pazgier, M., Li, C., Mao, Y., Lv, Y., Gu, B., Wei, G., Yuan, W., Zhan, C. et al. (2010) D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc. Natl Acad. Sci. USA, 107, 14321-14326.
78. Bhatia, K., Huppi, K., Spangler, G., Siwarski, D., Iyer, R. and Magrath, I. (1993) Point mutations in the C-Mcy transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet, 5, 56-61.
79. Mittag, T., Orlicky, S., Choy, W.Y., Tang, X., Lin, H., Sicheri, F., Kay, L.E., Tyers, M. and Forman-Kay, J.D. (2008) Dynamic equilibrium engagement of a polyvalent ligand with a single-site receptor. Proc. Natl Acad. Sci. USA, 105, 17772-17777.
80. Borg, M., Mittag, T., Pawson, T., Tyers, M., Forman-Kay, J.D. and Chan, H.S. (2007) Polyelectrostatic interactions of disordered ligands suggest a physical basis for ultrasensitiviyt. Proc. Natl Acad. Sci. USA, 104, 9650-9655.
81. Hateboer, G., Timmers, H.T.M., Rustgi, A.K., Billaud, M., Vantveer, L.J. and Bernards, R. (1993) TATA-binding protein and the retinoblastoma gene-product bind to overlapping epitopes on C-Mcy and adenovirus E1A protein. Proc. Natl Acad. Sci. USA, 90, 8489-8493.